Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults.

Trial Profile

Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2012

At a glance

  • Drugs NDV 3 (Primary)
  • Indications Candidiasis; Staphylococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Dec 2012 Results published in Vaccine, according to a NovaDigm Therapeutics media release.
    • 21 May 2012 Actual end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top